Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

9.92
-0.4800-4.62%
Volume:406.46K
Turnover:4.06M
Market Cap:880.20M
PE:-2.94
High:10.29
Open:10.29
Low:9.86
Close:10.40
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:1.78
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:18.17
PE(LYR):-3.12

Loading ...

Kura Oncology-Backed Caspian Advances KO-7246 Toward Phase 1 Diabetes Proof-of-Concept Study

Reuters
·
3 hours ago

Kura Oncology - Ind-Enabling Development Underway for Phase 1 Proof-of-Concept Study of Ko-7246

THOMSON REUTERS
·
3 hours ago

Caspian Therapeutics and Kura Oncology Outline Ko-7246 Development Strategy in Diabetes

THOMSON REUTERS
·
3 hours ago

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

GlobeNewswire
·
3 hours ago

Kura Oncology-Backed Caspian Plans Phase 1 Study of Diabetes Drug Candidate KO-7246

Reuters
·
Oct 07

Kura Oncology Grants Inducement Stock Options for 128,250 Shares to Nine New Hires

Reuters
·
Oct 02

Press Release: Kura Oncology Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
Oct 02

Kura Oncology Initiated at Overweight by JP Morgan

Dow Jones
·
Oct 01

JPMorgan Initiates Kura Oncology at Overweight With $30 Price Target

MT Newswires Live
·
Oct 01

Kura Oncology initiated with an Overweight at JPMorgan

TIPRANKS
·
Oct 01

Kura Oncology, - Caspian and Kura Announce Ko-7246 as Potential Best-in-Class Menin Inhibitor for Diabetes

THOMSON REUTERS
·
Sep 29

Kura Oncology-Backed Caspian Advances KO-7246 Menin Inhibitor Toward First-in-Human Diabetes Trials

Reuters
·
Sep 29

Kura Oncology CSO Francis Burrows Disposes of Common Shares Worth $224,435.31

Reuters
·
Sep 26

Kura Oncology CFO Jennifer Fulk Files Initial Beneficial Ownership Statement

Reuters
·
Sep 11

Kura Oncology (KURA) Receives a Buy from Leerink Partners

TIPRANKS
·
Sep 10

Kura Oncology Launches Caspian Therapeutics, Targets Clinical Proof-of-Concept for Diabetes Drug KO-7246 After USD 50 Million Financing

Reuters
·
Sep 09

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

THOMSON REUTERS
·
Sep 09

Kura Oncology Names Jennifer Fulk Finance Chief

MT Newswires Live
·
Sep 08

Kura Oncology Appoints Jennifer Fulk as New CFO

TIPRANKS
·
Sep 08

Kura Oncology Names Jennifer Fulk Chief Financial Officer

Dow Jones
·
Sep 08